Dynamin regulates L cell secretion in human gut.


Journal

Molecular and cellular endocrinology
ISSN: 1872-8057
Titre abrégé: Mol Cell Endocrinol
Pays: Ireland
ID NLM: 7500844

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 24 11 2020
revised: 01 06 2021
accepted: 13 07 2021
pubmed: 19 7 2021
medline: 27 1 2022
entrez: 18 7 2021
Statut: ppublish

Résumé

The mechanochemical enzyme dynamin mediates endocytosis and regulates neuroendocrine cell exocytosis. Enteroendocrine L cells co-secrete the anorectic gut hormones glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) postprandially and is a potential therapeutic target for metabolic diseases. In the present study, we aimed to determine if dynamin is implicated in human L cell secretion. Western blot was performed on the murine L cell line GLUTag. Static incubation of human colonic mucosae with activators and inhibitors of dynamin was carried out. GLP-1 and PYY contents of the secretion supernatants were assayed using ELISA. s: Both dynamin I and II are expressed in GLUTag cells. The dynamin activator Ryngo 1-23 evoked significant GLP-1 and PYY release from human colonic mucosae while the dynamin inhibitor Dynole 3-42 significantly inhibited release triggered by known L cell secretagogues. Thus, the cell signaling regulator dynamin is able to bi-directionally regulate L cell hormone secretion in the human gut and may represent a novel target for gastrointestinal-targeted metabolic drug development.

Sections du résumé

BACKGROUND
The mechanochemical enzyme dynamin mediates endocytosis and regulates neuroendocrine cell exocytosis. Enteroendocrine L cells co-secrete the anorectic gut hormones glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) postprandially and is a potential therapeutic target for metabolic diseases. In the present study, we aimed to determine if dynamin is implicated in human L cell secretion.
METHODS
Western blot was performed on the murine L cell line GLUTag. Static incubation of human colonic mucosae with activators and inhibitors of dynamin was carried out. GLP-1 and PYY contents of the secretion supernatants were assayed using ELISA.
RESULTS AND CONCLUSION
s: Both dynamin I and II are expressed in GLUTag cells. The dynamin activator Ryngo 1-23 evoked significant GLP-1 and PYY release from human colonic mucosae while the dynamin inhibitor Dynole 3-42 significantly inhibited release triggered by known L cell secretagogues. Thus, the cell signaling regulator dynamin is able to bi-directionally regulate L cell hormone secretion in the human gut and may represent a novel target for gastrointestinal-targeted metabolic drug development.

Identifiants

pubmed: 34274446
pii: S0303-7207(21)00242-2
doi: 10.1016/j.mce.2021.111398
pii:
doi:

Substances chimiques

Culture Media 0
Cyanoacrylates 0
Indoles 0
Ryngo 1-23 0
Tyrphostins 0
dynole 34-2 0
Peptide YY 106388-42-5
Glucagon-Like Peptide 1 89750-14-1
Dynamin I EC 3.5.1.50
DNM2 protein, human EC 3.6.5.5
Dynamin II EC 3.6.5.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111398

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Emily Wl Sun (EW)

Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.

Dusan Matusica (D)

Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.

David A Wattchow (DA)

Flinders Medical Centre, Bedford Park, SA, Australia.

Adam McCluskey (A)

Chemistry, School of Environmental and Life Sciences, The University of Newcastle, Callaghan, NSW, Australia.

Philip J Robinson (PJ)

Cell Signalling Unit, Children's Medical Research Institute, The University of Sydney, Westmead, NSW, Australia.

Damien J Keating (DJ)

Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia. Electronic address: damien.keating@flinders.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH